SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at the Biotech Showcase 2026 investor conference at the Hilton Union Square in San Francisco on January 13, 2026 at 3:00 p.m. Pacific Standard Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at the Biotech Showcase 2026 investor conference at the Hilton Union Square in San Francisco on January 13, 2026 at 3:00 p.m. Pacific Standard Time. The presentation will be streamed live on the company website and a replay will be posted at approximately 6:00 p.m. PST on January 13, 2026 and remain available for up to 30 days after posting.
SeaStar management will also meet with investors in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference from January 12–14, 2026.
Details
News Market Reaction – ICU
On Jan 6, the day this news came out, ICU closed 0.39% below the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference date
- January 13, 2026
- Biotech Showcase 2026 presentation date
- Presentation time
- 3:00 p.m. PST
- Live Biotech Showcase presentation
- Replay time
- 6:00 p.m. PST
- Replay posting time on January 13, 2026
- Replay availability
- 30 days
- Replay accessible following posting
- J.P. Morgan dates
- January 12–14, 2026
- Management meetings during 44th Annual J.P. Morgan Healthcare Conference
Historical Context
-
Announced 1-for-10 reverse split to address Nasdaq minimum bid requirement.
-
FDA allowed SAVE registry enrollment reduction for QUELIMMUNE pediatric AKI surveillance.
-
CEO scheduled presentation at NobleCon21 with replay available for 30 days.
-
Appointment of experienced healthcare CFO Michael Messinger to support growth.
-
Q3 2025 results plus QUELIMMUNE commercial data and NEUTRALIZE-AKI trial progress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time.
The live presentation will be available on the Company's website and can be accessed here. A replay of the presentation will be available at approximately 6:00 p.m. Pacific Standard Time on January 13, 2026, and can be accessed here. The replay will be available for up to 30 days following its posting.
Additionally, SeaStar Medical’s management team will be meeting with investors in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference from January 12-14, 2026.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.